NervGen Q2 FY26 net loss widens to C$29.2 million

Reuters2026/08/13 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NervGen posted a Q2 net loss of C$29.2 million, or C$0.32 per share, versus a C$9.1 million loss a year earlier.
Cash and cash equivalents climbed to C$86.8 million at June 30, 2026, from C$22.1 million at Dec. 31, 2025.
R&D expenses rose to C$7.9 million from C$2.7 million, driven by RESTORE start-up costs, manufacturing, and toxicology studies.
G&A expenses increased to C$4.3 million from C$3.8 million, on higher stock-based compensation and insurance tied to the Nasdaq listing.
RESTORE Phase 3 screening is expected to start in September 2026, with enrollment completion still targeted for 2H 2027 and topline data in 1H 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809319) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NervGen Q2 FY26 net loss widens to C$29.2 million

You may also like

Crypto prices